Dr. Ashraf R. Aziz
Claim this profileKaiser Permanente-Baldwin Park
Studies Lymphoma
Studies Leukemia
11 reported clinical trials
31 drugs studied
Area of expertise
1Lymphoma
Stage IV
Stage III
MYC positive
2Leukemia
13q positive
13q negative
12 positive
Affiliated Hospitals
Clinical Trials Ashraf R. Aziz is currently running
Oral Azacitidine + R-miniCHOP
for Diffuse Large B-Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Recruiting1 award Phase 2 & 314 criteria
SPd vs EloPd Chemotherapy
for Multiple Myeloma
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Recruiting2 awards Phase 318 criteria
More about Ashraf R. Aziz
Clinical Trial Related5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Ashraf R. Aziz has experience with
- Obinutuzumab
- Lenalidomide
- Cyclophosphamide
- Doxorubicin Hydrochloride
- Vincristine Sulfate
- Prednisone
Breakdown of trials Ashraf R. Aziz has run
Lymphoma
Leukemia
Plasma Cell Neoplasm
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ashraf R. Aziz specialize in?
Ashraf R. Aziz focuses on Lymphoma and Leukemia. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Ashraf R. Aziz currently recruiting for clinical trials?
Yes, Ashraf R. Aziz is currently recruiting for 5 clinical trials in Baldwin Park California. If you're interested in participating, you should apply.
Are there any treatments that Ashraf R. Aziz has studied deeply?
Yes, Ashraf R. Aziz has studied treatments such as Obinutuzumab, Lenalidomide, Cyclophosphamide.
What is the best way to schedule an appointment with Ashraf R. Aziz?
Apply for one of the trials that Ashraf R. Aziz is conducting.
What is the office address of Ashraf R. Aziz?
The office of Ashraf R. Aziz is located at: Kaiser Permanente-Baldwin Park, Baldwin Park, California 91706 United States. This is the address for their practice at the Kaiser Permanente-Baldwin Park.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.